Evidence mapPaperPMID 42443151Full record

ReviewSignal transduction and targeted therapy2026

Multiple organ dysfunction syndrome: molecular mechanisms and therapeutic strategies.

Xuan Xu, Jinwen Chen, Yuqing Feng, Chun Zou, Xujun Peng, Zhenyu Wang, Yuxuan Ma, Yuxin Xie, Huiling Li, Dongshan Zhang

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xuan XuDepartment of Critical Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Jinwen ChenDepartment of Emergency Medicine, Hunan Aerospace Hospital, Changsha, China.
Yuqing FengDepartment of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Chun ZouDepartment of Critical Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xujun PengDepartment of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Zhenyu WangDepartment of Critical Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuxuan MaDepartment of Critical Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yuxin XieDepartment of Critical Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. 445926246@qq.com.
Huiling LiDepartment of Ophthalmology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. lihuiling@csu.edu.cn.
Dongshan ZhangDepartment of Critical Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. dongshanzhang@csu.edu.cn.ORCID http://orcid.org/0000-0002-7387-4804

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple organ dysfunction syndrome presents a significant challenge in clinical critical care, characterized by the progressive or simultaneous failure of two or more organ systems following severe insults such as infection, trauma, acute pancreatitis, shock, burns, or other major events. Recent advancements in research have deepened the understanding of organ dysfunction, with a shift toward investigating organ injury and organ-specific diseases. The pathogenesis of MODS is intricate and driven by dynamic interactions across multiple levels, including inflammatory responses, microcirculatory disruptions, coagulation abnormalities, cell death, DNA damage and the production of reactive oxygen species. Recent innovations in single-cell technologies, spatial omics and organoid models have opened new avenues for exploring intercellular signaling, targeting damaged tissues and advancing drug development. Current therapeutic approaches for MODS involve comprehensive strategies, such as aggressive management of underlying causes, organ support, modulation of immune and inflammatory responses, nutritional intervention and stabilization of the internal environment. Despite these efforts, mortality rates remain high, and therapeutic advancements have yet to yield optimal results. This highlights the urgent need for continued research to translate scientific discoveries into clinical breakthroughs. Further exploration of the disease's pathogenesis, identification of early diagnostic biomarkers and development of novel, effective treatments are crucial to improving treatment outcomes and reducing mortality in critically ill patients.

Indexed as

Multiple Organ FailureAnimalsDNA DamageHumansReactive Oxygen SpeciesReactive Oxygen Species

Identifiers

PMID42443151
PMCPMC13365620

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.